Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
Background: We aimed to review the systematic economic evaluation of denosumab versus than alternative drugs and oral bisphosphonates of postmenopausal osteoporosis in women and help health system policy makers for prioritizing and optimally allocate limited health resources. Methods: We examine...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2022-07-01
|
| Series: | Iranian Journal of Public Health |
| Subjects: | |
| Online Access: | https://ijph.tums.ac.ir/index.php/ijph/article/view/24562 |
| _version_ | 1818507929458835456 |
|---|---|
| author | Shahin Nargesi Saeed Husseini Barghazan Nadia Sani'ee Asma Rashki Kemmak |
| author_facet | Shahin Nargesi Saeed Husseini Barghazan Nadia Sani'ee Asma Rashki Kemmak |
| author_sort | Shahin Nargesi |
| collection | DOAJ |
| description |
Background: We aimed to review the systematic economic evaluation of denosumab versus than alternative drugs and oral bisphosphonates of postmenopausal osteoporosis in women and help health system policy makers for prioritizing and optimally allocate limited health resources.
Methods: We examined the databases of PubMed, Web of Science, Embase, Scopus, Cochrane Library, ProQuest. Strategy search was designed based on keywords. Inclusion criteria were: studies that conducted economic evaluation denosumab compared to oral bisphosphonates for the treatment of osteoporosis in postmenopausal women. Cost-effectiveness studies conducted using decision analysis models based on the economic evaluation approach; studies with available full-text papers; and studies written in English and published between 2010 and 2020. After selecting articles based on inclusion and exclusion criteria, data were extracted and the results were summarized. The quality of the articles was evaluated using the CHEERS checklist.
Results: Among 214 initial studies, 8 studies met the inclusion criteria. Most studies focused on the cost-effectiveness of denosumab compared with oral bisphosphonates for the treatment of osteoporosis. The study agreed interval ranged from 3 months to 5 years. The costs investigated in the studies were direct medical costs. In most studies, the use of denosumab significantly prevented fractures.
Conclusion: Denosumab is generally more cost-effective than alternative drugs and oral bisphosphonates (alendronate, risedronate, strontium ranelate, ibandronate, and untreated).
|
| first_indexed | 2024-12-10T22:24:52Z |
| format | Article |
| id | doaj.art-0977adaa43894ff8831635886df85827 |
| institution | Directory Open Access Journal |
| issn | 2251-6085 2251-6093 |
| language | English |
| last_indexed | 2024-12-10T22:24:52Z |
| publishDate | 2022-07-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Public Health |
| spelling | doaj.art-0977adaa43894ff8831635886df858272022-12-22T01:31:13ZengTehran University of Medical SciencesIranian Journal of Public Health2251-60852251-60932022-07-0151710.18502/ijph.v51i7.10084Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic ReviewShahin Nargesi0Saeed Husseini Barghazan1Nadia Sani'ee2Asma Rashki Kemmak3Department of Public Health, Faculty of Health, Ilam University of Medical Sciences, Ilam, IranDepartment of Health Economic, School of Health Management and Information Sciences, Iran University of Medical Sciences, Teh-ran, IranDepartment of Medical Library and Information Sciences, Student Research Committee, Iran University of Medical Sciences, Tehran, IranDepartment of Health Economic, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran Background: We aimed to review the systematic economic evaluation of denosumab versus than alternative drugs and oral bisphosphonates of postmenopausal osteoporosis in women and help health system policy makers for prioritizing and optimally allocate limited health resources. Methods: We examined the databases of PubMed, Web of Science, Embase, Scopus, Cochrane Library, ProQuest. Strategy search was designed based on keywords. Inclusion criteria were: studies that conducted economic evaluation denosumab compared to oral bisphosphonates for the treatment of osteoporosis in postmenopausal women. Cost-effectiveness studies conducted using decision analysis models based on the economic evaluation approach; studies with available full-text papers; and studies written in English and published between 2010 and 2020. After selecting articles based on inclusion and exclusion criteria, data were extracted and the results were summarized. The quality of the articles was evaluated using the CHEERS checklist. Results: Among 214 initial studies, 8 studies met the inclusion criteria. Most studies focused on the cost-effectiveness of denosumab compared with oral bisphosphonates for the treatment of osteoporosis. The study agreed interval ranged from 3 months to 5 years. The costs investigated in the studies were direct medical costs. In most studies, the use of denosumab significantly prevented fractures. Conclusion: Denosumab is generally more cost-effective than alternative drugs and oral bisphosphonates (alendronate, risedronate, strontium ranelate, ibandronate, and untreated). https://ijph.tums.ac.ir/index.php/ijph/article/view/24562Cost benefit analysisDenosumabOsteoporosisPostmenopausalSystematic review |
| spellingShingle | Shahin Nargesi Saeed Husseini Barghazan Nadia Sani'ee Asma Rashki Kemmak Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review Iranian Journal of Public Health Cost benefit analysis Denosumab Osteoporosis Postmenopausal Systematic review |
| title | Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review |
| title_full | Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review |
| title_fullStr | Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review |
| title_full_unstemmed | Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review |
| title_short | Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review |
| title_sort | economic evaluation of denosumab for treatment of postmenopausal osteoporosis a systematic review |
| topic | Cost benefit analysis Denosumab Osteoporosis Postmenopausal Systematic review |
| url | https://ijph.tums.ac.ir/index.php/ijph/article/view/24562 |
| work_keys_str_mv | AT shahinnargesi economicevaluationofdenosumabfortreatmentofpostmenopausalosteoporosisasystematicreview AT saeedhusseinibarghazan economicevaluationofdenosumabfortreatmentofpostmenopausalosteoporosisasystematicreview AT nadiasaniee economicevaluationofdenosumabfortreatmentofpostmenopausalosteoporosisasystematicreview AT asmarashkikemmak economicevaluationofdenosumabfortreatmentofpostmenopausalosteoporosisasystematicreview |